Literature DB >> 25875700

Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Olga Nikolajeva1, Austen Worth, Rosie Hague, Nuria Martinez-Alier, Joanne Smart, Stuart Adams, E Graham Davies, H Bobby Gaspar.   

Abstract

PURPOSE: Adenosine deaminase (ADA) deficiency is a systemic disorder of purine metabolism. Deficiency of the purine salvage enzyme ADA leads to the build-up of the toxic metabolites, deoxyadenosine triphosphate and deoxyadenosine. ADA is ubiquitously expressed in all tissues of the body but most profoundly affects lymphocyte development and function leading to severe combined immunodeficiency (SCID). Unlike most other forms of SCID, ADA deficiency also results in non-immunologic manifestations. Associations between ADA deficiency and sensorineural hearing loss, behavioural abnormalities, non-infectious pulmonary disease and skeletal dysplasia are all recognised, and affect the long term outcome for these patients. Identification of new non-immunological manifestations and clinical presentations of ADA deficiency is essential to allow early optimisation of supportive care. METHODS AND
RESULTS: Here we report four patients with ADA deficiency whose presenting feature was haemolytic uremic syndrome (HUS). 3 of 4 patients were diagnosed with ADA deficiency only after developing HUS, and one diagnosis was made post mortem, after a sibling was diagnosed with SCID. Shiga-toxigenic organisms were not isolated from any of the patients. 2 patients made a good recovery from their HUS with supportive treatment and initiation of PEG-ADA. Both remain well on enzyme replacement with mild or no residual renal impairment.
CONCLUSIONS: Clinicians should be aware of this previously unreported non-immunologic manifestation of ADA deficiency.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25875700     DOI: 10.1007/s10875-015-0158-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  46 in total

1.  Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency.

Authors:  Eyal Grunebaum; Ernest Cutz; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2012-03-10       Impact factor: 10.793

Review 2.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  Adenosine deaminase deficiency in adults.

Authors:  H Ozsahin; F X Arredondo-Vega; I Santisteban; H Fuhrer; P Tuchschmid; W Jochum; A Aguzzi; H M Lederman; A Fleischman; J A Winkelstein; R A Seger; M S Hershfield
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

4.  Hemolytic uremic syndrome related to cryptosporidium infection in an immunocompetent child.

Authors:  Nikoleta Printza; Evdoxia Sapountzi; John Dotis; Fotios Papachristou
Journal:  Pediatr Int       Date:  2013-12       Impact factor: 1.524

Review 5.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

Authors:  N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

6.  Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency.

Authors:  M E Bollinger; F X Arredondo-Vega; I Santisteban; K Schwarz; M S Hershfield; H M Lederman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

Review 7.  How I treat ADA deficiency.

Authors:  H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

8.  ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.

Authors:  Aisha V Sauer; Emanuela Mrak; Raisa Jofra Hernandez; Elena Zacchi; Francesco Cavani; Miriam Casiraghi; Eyal Grunebaum; Chaim M Roifman; Maria C Cervi; Alessandro Ambrosi; Filippo Carlucci; Maria Grazia Roncarolo; Anna Villa; Alessandro Rubinacci; Alessandro Aiuti
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

9.  Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.

Authors:  M Wakamiya; M R Blackburn; R Jurecic; M J McArthur; R S Geske; J Cartwright; K Mitani; S Vaishnav; J W Belmont; R E Kellems
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies.

Authors:  Penny Titman; Elizabeth Pink; Emily Skucek; Katherine O'Hanlon; Tim J Cole; Jane Gaspar; Jinhua Xu-Bayford; Alison Jones; Adrian J Thrasher; E Graham Davies; Paul A Veys; H Bobby Gaspar
Journal:  Blood       Date:  2008-07-21       Impact factor: 22.113

View more
  5 in total

Review 1.  Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.

Authors:  Donald B Kohn; Michael S Hershfield; Jennifer M Puck; Alessandro Aiuti; Annaliesse Blincoe; H Bobby Gaspar; Luigi D Notarangelo; Eyal Grunebaum
Journal:  J Allergy Clin Immunol       Date:  2018-09-05       Impact factor: 10.793

2.  Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.

Authors:  Maria Pia Cicalese; Francesca Ferrua; Laura Castagnaro; Katie Rolfe; Erika De Boever; Rickey R Reinhardt; Jonathan Appleby; Maria Grazia Roncarolo; Alessandro Aiuti
Journal:  Mol Ther       Date:  2018-01-04       Impact factor: 11.454

3.  Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia.

Authors:  Serena I Tripodi; Paola Corti; Silvia Giliani; Arnalda Lanfranchi; Andrea Biondi; Raffaele Badolato
Journal:  Front Pediatr       Date:  2018-10-01       Impact factor: 3.418

Review 4.  Adenosine Deaminase Deficiency - More Than Just an Immunodeficiency.

Authors:  Kathryn V Whitmore; Hubert B Gaspar
Journal:  Front Immunol       Date:  2016-08-16       Impact factor: 7.561

Review 5.  Adenosine deaminase deficiency: a review.

Authors:  Aisling M Flinn; Andrew R Gennery
Journal:  Orphanet J Rare Dis       Date:  2018-04-24       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.